-
UnitedHealth CEO Highlights Hospitals, Doctors, Pharma's Role In Soaring Health Care Costs
Thursday, January 16, 2025 - 5:28pm | 578Read More...UnitedHealth Group, Inc. (NYSE:UNH) reported its financial results on Thursday after a tumultuous fourth quarter that included the murder of UnitedHealthcare division CEO Brian Thompson and broad public outrage over the nation's health care system. What To Know: UnitedHealth posted mixed...
-
UnitedHealth Group Q4 Earnings Preview: First Report Since Insurance CEO's Murder Comes With Questions On Company's Future
Wednesday, January 15, 2025 - 4:55pm | 966Read More...Investors and analysts could turn attention to how UnitedHealth Group (NYSE:UNH) will replace its insurance unit CEO Brian Thompson, who was fatally shot in December, and how the company will keep public trust as the sector comes under increased scrutiny when the company reports fourth-quarter...
-
UnitedHealth Group CEO Reportedly Says Company Will Hit Financial Records: Exec's Murder, Public Outcry Are Backdrop For Q4 Earnings
Tuesday, December 31, 2024 - 12:39pm | 902Read More...The death of UnitedHealthcare CEO Brian Thompson shocked the health insurance industry and could be on the minds of investors and analysts when the insurance company's parent UnitedHealth Group (NYSE:UNH) reports fourth-quarter financial results on Jan. 16. What Happened: UnitedHealth Group has...
-
GlaxoSmithKline Posts Ill EPS, Healthy Revenue
Wednesday, April 24, 2013 - 10:34am | 412Read More...GlaxoSmithKline (NYSE: GSK) is up on Wednesday after missing on first-quarter EPS but beating on revenue. The Brentford, UK-based firm finished with earnings of $0.41 per share, falling far short of the $0.77 Wall Street consensus. Revenue dropped two percent to $9.88 billion, but topped...
-
GlaxoSmithKline plc (GSK) Sees Little Threat To Advair From Generic Competition
Wednesday, January 13, 2010 - 4:13pm | 146Read More...GlaxoSmithKline plc (ADR) (NYSE: GSK) sees little threat to its top selling drug Advair from generic competition, according to GlaxoSmithKline Chief Executive Andrew Witty. Speaking at the JPMorgan (NYSE: JPM) Healthcare Conference, Mr. Witty said that it is very difficult to make a generic and...
